Allison Bratzel
Stock Analyst at Piper Sandler
(4.38)
# 333
Out of 5,152 analysts
59
Total ratings
59.57%
Success rate
17.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRRK Scholar Rock Holding | Maintains: Overweight | $51 → $58 | $47.43 | +22.29% | 5 | Mar 4, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $87 → $100 | $79.45 | +25.87% | 5 | Feb 27, 2026 | |
| TVTX Travere Therapeutics | Maintains: Neutral | $35 → $38 | $28.18 | +34.85% | 4 | Feb 6, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $84 | $60.43 | +39.00% | 1 | Feb 6, 2026 | |
| INCY Incyte | Maintains: Overweight | $102 → $110 | $98.86 | +11.27% | 4 | Feb 6, 2026 | |
| AKBA Akebia Therapeutics | Maintains: Overweight | $6 → $4 | $1.25 | +220.00% | 2 | Feb 6, 2026 | |
| REPL Replimune Group | Maintains: Overweight | $13 → $14 | $7.25 | +93.10% | 3 | Feb 5, 2026 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $3 → $4 | $2.19 | +82.65% | 1 | Feb 5, 2026 | |
| IOBT IO Biotech | Downgrades: Neutral | $3 → $0.5 | $0.33 | +50.69% | 2 | Jan 26, 2026 | |
| TYRA Tyra Biosciences | Maintains: Overweight | $33 → $42 | $35.27 | +19.08% | 2 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $30 | $7.41 | +304.86% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $820 → $930 | $749.56 | +24.07% | 15 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $112 | $116.77 | -4.08% | 1 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $115 | $21.80 | +427.52% | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $9.74 | +166.94% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $23 | $29.63 | -22.38% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $22 | $29.52 | -25.47% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 | $1.15 | +247.83% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $20 | $6.14 | +225.73% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $20 | $3.63 | +450.96% | 1 | Oct 13, 2023 |
Scholar Rock Holding
Mar 4, 2026
Maintains: Overweight
Price Target: $51 → $58
Current: $47.43
Upside: +22.29%
Ionis Pharmaceuticals
Feb 27, 2026
Maintains: Overweight
Price Target: $87 → $100
Current: $79.45
Upside: +25.87%
Travere Therapeutics
Feb 6, 2026
Maintains: Neutral
Price Target: $35 → $38
Current: $28.18
Upside: +34.85%
BioMarin Pharmaceutical
Feb 6, 2026
Maintains: Overweight
Price Target: $122 → $84
Current: $60.43
Upside: +39.00%
Incyte
Feb 6, 2026
Maintains: Overweight
Price Target: $102 → $110
Current: $98.86
Upside: +11.27%
Akebia Therapeutics
Feb 6, 2026
Maintains: Overweight
Price Target: $6 → $4
Current: $1.25
Upside: +220.00%
Replimune Group
Feb 5, 2026
Maintains: Overweight
Price Target: $13 → $14
Current: $7.25
Upside: +93.10%
ALX Oncology Holdings
Feb 5, 2026
Maintains: Overweight
Price Target: $3 → $4
Current: $2.19
Upside: +82.65%
IO Biotech
Jan 26, 2026
Downgrades: Neutral
Price Target: $3 → $0.5
Current: $0.33
Upside: +50.69%
Tyra Biosciences
Jan 23, 2026
Maintains: Overweight
Price Target: $33 → $42
Current: $35.27
Upside: +19.08%
Nov 11, 2025
Maintains: Overweight
Price Target: $28 → $30
Current: $7.41
Upside: +304.86%
Nov 4, 2025
Maintains: Overweight
Price Target: $820 → $930
Current: $749.56
Upside: +24.07%
Jul 29, 2025
Maintains: Overweight
Price Target: $70 → $112
Current: $116.77
Upside: -4.08%
Mar 17, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $21.80
Upside: +427.52%
Feb 18, 2025
Initiates: Overweight
Price Target: $26
Current: $9.74
Upside: +166.94%
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $29.63
Upside: -22.38%
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $29.52
Upside: -25.47%
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $1.15
Upside: +247.83%
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $6.14
Upside: +225.73%
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $3.63
Upside: +450.96%